Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684217 | 0.78 | ADORA2B (0.38) | SYKFLT3AURKB | |
| SCHEMBL1067757 | 0.75 | ADORA2A (0.47) | ALDH1A1 | |
| SCHEMBL1065416 | 0.72 | ADORA2B (0.56) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2685558 | 0.69 | ADORA2B (0.41) | SYKFLT3 | |
| SCHEMBL1065067 | 0.67 | ADORA2A (0.44) | SYKFLT3 | |
| SCHEMBL4407389 | 0.66 | ADORA2B (0.59) | — | |
| SCHEMBL1063503 | 0.65 | ADORA2A (0.50) | ALDH1A1 | |
| SCHEMBL1720688 | 0.63 | CACNA2D1 (0.30) | — | |
| SCHEMBL1065318 | 0.63 | ADORA2B (0.58) | — | |
| SCHEMBL2686196 | 0.62 | ADORA2B (0.42) | SYKFLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | claimed |
| EP-2405917-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | Advinus Therapeutics Private Limited (IN) | 2012-01-18 | — | — | EP | claimed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | claimed |
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | disclosed |
| EP-2405917-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | Advinus Therapeutics Private Limited (IN) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | disclosed |